Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. (SHE:300357)

SHE:300357 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,146	1,119	1,171	840.69	649.99	583.68
Trading Asset Securities	140.66	196.09	117.39	295.05	370.93	307.03
Cash & Short-Term Investments	1,286	1,315	1,289	1,136	1,021	890.71
Cash Growth	0.24%	2.03%	13.47%	11.25%	14.62%	12.44%
Accounts Receivable	230.82	251.04	202.92	254.31	238.12	206.77
Other Receivables	7.65	-	-	19.81	11.13	8.57
Receivables	238.46	251.04	202.92	274.12	249.26	215.35
Inventory	57.47	57.73	59.04	48.41	53.75	48.33
Other Current Assets	28.18	27.78	19.17	18.86	17.58	16.55
Total Current Assets	1,610	1,651	1,570	1,477	1,342	1,171
Property, Plant & Equipment	791.5	780.09	704.84	444.61	301.62	240.16
Long-Term Investments	77.74	77.94	74.21	78.4	83.35	13.86
Other Intangible Assets	159.14	162.79	161.38	139.67	94	61.01
Long-Term Deferred Tax Assets	5.82	5.6	5.03	4.87	5.81	4.9
Long-Term Deferred Charges	27.02	25.27	34.38	53.2	86.05	113.89
Other Long-Term Assets	4.01	5.94	12.42	-	19.63	-
Total Assets	2,676	2,709	2,562	2,198	1,932	1,605
Accounts Payable	29.54	47.77	7.99	7.68	5.08	5.66
Accrued Expenses	20.76	35.13	33.57	29.89	35.54	23.15
Short-Term Debt	5.05	12.63	34.39	-	-	-
Current Portion of Leases	3.94	5.03	6.8	3.98	5.86	-
Current Income Taxes Payable	15.83	10.56	9.26	26.08	50.32	9.59
Current Unearned Revenue	0.56	0.51	0.38	0.42	0.42	0.44
Other Current Liabilities	8.81	70.95	84.64	34.71	10.78	16.57
Total Current Liabilities	84.49	182.58	177.04	102.75	108	55.42
Long-Term Leases	1.37	7.93	21.26	12.28	1.95	-
Long-Term Unearned Revenue	33.1	33.53	30.93	27.43	24.91	20.63
Long-Term Deferred Tax Liabilities	0.1	0.17	0.2	0.08	0.5	0.56
Other Long-Term Liabilities	26.08	26.08	29.03	28.22	-	-
Total Liabilities	145.13	250.3	258.46	170.76	135.36	76.61
Common Stock	523.58	523.58	523.58	523.58	523.58	523.58
Additional Paid-In Capital	128.19	128.19	128.19	128.19	128.19	128.19
Retained Earnings	1,776	1,702	1,533	1,328	1,084	803.26
Comprehensive Income & Other	0.04	0.04	0.03	0.03	0	0.87
Total Common Equity	2,428	2,354	2,185	1,980	1,736	1,456
Minority Interest	102.33	105.12	118.61	47.49	60.54	72.24
Shareholders' Equity	2,530	2,459	2,304	2,027	1,797	1,528
Total Liabilities & Equity	2,676	2,709	2,562	2,198	1,932	1,605
Total Debt	10.37	25.59	62.44	16.26	7.81	-
Net Cash (Debt)	1,276	1,289	1,226	1,119	1,013	890.71
Net Cash Growth	5.69%	5.14%	9.54%	10.50%	13.74%	12.44%
Net Cash Per Share	2.44	2.46	2.34	2.14	1.93	1.70
Filing Date Shares Outstanding	523.58	523.58	523.58	523.58	523.58	523.58
Total Common Shares Outstanding	523.58	523.58	523.58	523.58	523.58	523.58
Working Capital	1,526	1,469	1,393	1,374	1,234	1,116
Book Value Per Share	4.64	4.50	4.17	3.78	3.32	2.78
Tangible Book Value	2,269	2,191	2,024	1,840	1,642	1,395
Tangible Book Value Per Share	4.33	4.18	3.87	3.51	3.14	2.66
Buildings	-	428.52	423.31	175.67	137.89	137.89
Machinery	-	135.42	115.99	95.51	77.11	71.89
Construction In Progress	-	323.16	227.86	226.24	140.33	80.46

Source: S&P Global Market Intelligence. Standard template. Financial Sources.